Cerebral edema in pediatric ketoacidosis

小儿酮症酸中毒脑水肿

基本信息

  • 批准号:
    6851388
  • 负责人:
  • 金额:
    $ 33.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-12-01 至 2009-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Diabetic ketoacidosis (DKA) occurs in 25-40% of children with new onset of type 1 diabetes, and occurs in children with established diabetes at a rate of approximately 8% per year. Cerebral edema (CE) is the most common serious complication of DKA in children, occurring in 1-5% of DKA episodes. CE has a high mortality rate (20-90%) and is the most common diabetes-related cause of death in children. The physiological mechanisms responsible for DKA-related CE are not understood. Previous studies by our group demonstrated that children at greatest risk for CE are those who present with greater dehydration and greater hypocapnia. The identification of these risk factors as those most strongly associated with CE suggests that central nervous system hypoperfusion may be an important factor in the pathogenesis of CE. Preliminary studies by our group in children with DKA and in an animal model of DKA support the hypothesis that cerebral hypoperfusion during untreated DKA may play a central role in causing CE and that hypersecretion of NaCI and water by the blood-brain barrier (BBB) may occur in this setting. We hypothesize that; (1) DKA results in stimulation of transport of NaCI and water by the BBB, (2) pharmacological interventions which block NaCI transport will decrease edema formation during DKA, (3) pharmacological interventions which rapidly restore cerebral perfusion will lead to more rapid normalization of cerebral metabolic abnormalities associated with DKA. In the current proposal, we aim to determine whether two interventions, bumetanide (a specific inhibitor of NaCl transport by the BBB), and mannitol (an osmotic agent which enhances cerebral perfusion) prevent or ameliorate CE in DKA and whether these agents improve cerebral metabolic abnormalities associated with DKA. We plan to conduct parallel studies in children with DKA and in an animal model of DKA to compare the effects of pharmacological interventions (bumetanide, mannitol and dexamethasone) on edema formation, cerebral perfusion and cerebral metabolism. In both the human and animal studies, we will use magnetic resonance (MR) imaging methods, (proton and phosphate MR spectroscopy, diffusion weighted imaging and perfusion weighted imaging) to study these interventions. Initial animal studies will provide information regarding the optimal treatment protocol to prevent or ameliorate CE in children with DKA. This initial animal data will form the basis for a randomized clinical trial of interventions for the prevention of CE in children with DKA which will be the main focus of the study.
描述(由申请人提供):糖尿病酮症酸中毒(DKA)发生在25-40%的新发1型糖尿病儿童中,并以每年约8%的速度发生在确诊糖尿病儿童中。脑水肿(CE)是儿童DKA最常见的严重并发症,发生在1-5%的DKA发作中。CE的死亡率很高(20-90%),是儿童中最常见的糖尿病相关死亡原因。DKA相关CE的生理机制尚不清楚。我们小组以前的研究表明,CE风险最大的儿童是那些存在严重脱水和严重低碳酸血症的儿童。这些危险因素与CE密切相关,表明中枢神经系统灌注不足可能是CE发病机制中的重要因素。我们小组在DKA儿童和DKA动物模型中的初步研究支持以下假设:未经治疗的DKA期间脑灌注不足可能在导致CE中起核心作用,并且在这种情况下可能发生血脑屏障(BBB)的NaCl和水分泌过多。我们假设;(1)DKA导致刺激BBB转运NaCl和水,(2)阻断NaCl转运的药理学干预将减少DKA期间的水肿形成,(3)快速恢复脑灌注的药理学干预将导致与DKA相关的脑代谢异常更快地正常化。在目前的建议中,我们的目的是确定两种干预措施,布美他尼(一种特定的抑制剂,NaCl运输的血脑屏障),甘露醇(渗透剂,增强脑灌注)预防或改善CE的DKA和这些药物是否改善脑代谢异常与DKA。我们计划在DKA儿童和DKA动物模型中进行平行研究,以比较药物干预(布美他尼、甘露醇和地塞米松)对水肿形成、脑灌注和脑代谢的影响。在人体和动物研究中,我们将使用磁共振(MR)成像方法(质子和磷酸盐MR波谱、弥散加权成像和灌注加权成像)来研究这些干预措施。初步动物研究将提供关于预防或改善DKA儿童CE的最佳治疗方案的信息。这些初始动物数据将构成DKA儿童CE预防干预措施的随机临床试验的基础,这将是本研究的主要重点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NICOLE S GLASER其他文献

NICOLE S GLASER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NICOLE S GLASER', 18)}}的其他基金

Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis
小儿糖尿病酮症酸中毒的液体治疗和脑损伤
  • 批准号:
    8519254
  • 财政年份:
    2010
  • 资助金额:
    $ 33.73万
  • 项目类别:
Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis
小儿糖尿病酮症酸中毒的液体治疗和脑损伤
  • 批准号:
    8051572
  • 财政年份:
    2010
  • 资助金额:
    $ 33.73万
  • 项目类别:
Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis
小儿糖尿病酮症酸中毒的液体治疗和脑损伤
  • 批准号:
    8644819
  • 财政年份:
    2010
  • 资助金额:
    $ 33.73万
  • 项目类别:
Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis
小儿糖尿病酮症酸中毒的液体治疗和脑损伤
  • 批准号:
    7759097
  • 财政年份:
    2010
  • 资助金额:
    $ 33.73万
  • 项目类别:
Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis
小儿糖尿病酮症酸中毒的液体治疗和脑损伤
  • 批准号:
    8248308
  • 财政年份:
    2010
  • 资助金额:
    $ 33.73万
  • 项目类别:
Cerebral edema in pediatric ketoacidosis
小儿酮症酸中毒脑水肿
  • 批准号:
    7154079
  • 财政年份:
    2004
  • 资助金额:
    $ 33.73万
  • 项目类别:
Cerebral edema in pediatric ketoacidosis
小儿酮症酸中毒脑水肿
  • 批准号:
    6986081
  • 财政年份:
    2004
  • 资助金额:
    $ 33.73万
  • 项目类别:
Cerebral edema in pediatric ketoacidosis
小儿酮症酸中毒脑水肿
  • 批准号:
    7545847
  • 财政年份:
    2004
  • 资助金额:
    $ 33.73万
  • 项目类别:
Cerebral edema in pediatric ketoacidosis
小儿酮症酸中毒脑水肿
  • 批准号:
    7340407
  • 财政年份:
    2004
  • 资助金额:
    $ 33.73万
  • 项目类别:

相似海外基金

ICF: Enhancing Blood-Brain Barrier Opening with Ultrasound and Microwaves for Targeted Drug Delivery
ICF:利用超声波和微波增强血脑屏障开放以实现靶向药物输送
  • 批准号:
    MR/Z503848/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.73万
  • 项目类别:
    Research Grant
Venom-derived blood-brain-barrier shuttles
毒液衍生的血脑屏障穿梭机
  • 批准号:
    DP230102707
  • 财政年份:
    2023
  • 资助金额:
    $ 33.73万
  • 项目类别:
    Discovery Projects
Development of blood-brain barrier-penetrating oligosaccharides
穿透血脑屏障寡糖的开发
  • 批准号:
    23K11852
  • 财政年份:
    2023
  • 资助金额:
    $ 33.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Defining mechanisms of blood-brain barrier dysfunction in cerebral small vessel disease using advanced 3D in vitro models.
使用先进的 3D 体外模型定义脑小血管疾病血脑屏障功能障碍的机制。
  • 批准号:
    MR/W027119/1
  • 财政年份:
    2023
  • 资助金额:
    $ 33.73万
  • 项目类别:
    Fellowship
Understanding suppression of transcytosis in formation of the blood-brain barrier (BBB) and how Calcrl/Ramp2 signalling limits BBB permeability
了解血脑屏障 (BBB) 形成过程中转胞吞作用的抑制以及 Calcrl/Ramp2 信号如何限制 BBB 通透性
  • 批准号:
    MR/X008215/1
  • 财政年份:
    2023
  • 资助金额:
    $ 33.73万
  • 项目类别:
    Research Grant
The blood-brain barrier and Alzheimer pathology
血脑屏障和阿尔茨海默病病理学
  • 批准号:
    10800246
  • 财政年份:
    2023
  • 资助金额:
    $ 33.73万
  • 项目类别:
Bisphenol-Induced Blood-Brain Barrier Dysfunction in Alzheimer’s Disease
双酚引起的阿尔茨海默氏病血脑屏障功能障碍
  • 批准号:
    10713025
  • 财政年份:
    2023
  • 资助金额:
    $ 33.73万
  • 项目类别:
Circadian Rhythms in Blood Brain Barrier Permeability and Increased Efficacy of Chemotherapy for Brain Metastases
血脑屏障通透性的昼夜节律和脑转移化疗疗效的提高
  • 批准号:
    10663717
  • 财政年份:
    2023
  • 资助金额:
    $ 33.73万
  • 项目类别:
Blood brain barrier integrity and immune dynamics contributing to neuropsychiatric sequela in COVID long-haulers
血脑屏障完整性和免疫动态导致新冠长途运输者的神经精神后遗症
  • 批准号:
    10688300
  • 财政年份:
    2023
  • 资助金额:
    $ 33.73万
  • 项目类别:
MicroRNAs, Mitochondria and the Blood-Brain Barrier - Therapeutic Targets for Stroke
MicroRNA、线粒体和血脑屏障——中风的治疗靶点
  • 批准号:
    10587899
  • 财政年份:
    2023
  • 资助金额:
    $ 33.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了